


Third Announcement



10th International Symposium Biological Therapy of Cancer from Disease to Targeted Therapy

co-organised by
Biotherapy Development Association (BDA)
European Society for Medical Oncology (ESMO)
National Cancer Institute (NCI)
Tumorzentrum Rhein-Main e.V.
Tumorzentrum München




www.bdaoncology.org

Munich, Germany
September 8 – 10, 2010

BTOCC10





10th International Symposium Biological Therapy of Cancer from Disease to Targeted Therapy

Due to the exciting developments of molecular biology during the past decade and our increasing understanding of the mechanisms relevant to the genesis of cancer, we are experiencing a transition from disease to target-oriented therapy. This has a strong impact on the development paradigm of cancer therapeutics.

To date, breakthroughs have mainly been achieved with therapeutic monoclonal antibodies or signal transduction inhibitors. Numerous further classes of biological agents are in clinical development and are expected to revolutionize medical therapy of cancer even more.

The 10th International Congress on "Biological Therapy of Cancer" will again be held in Munich, 8th – 10th September 2010 under the auspices of the Tumor Center Munich. Like the previous meetings, BTOC-10 will focus on the clinical development of a broad spectrum of anticancer agents with an emphasis on immunomodulatory agents such as monoclonal antibodies, vaccines and gene therapeutic approaches.

Call for Abstracts

Free communications and poster sessions are highlights of the conference.

Participants are invited to submit abstracts for poster presentations. A limited number will be selected for oral presentation.

All accepted abstracts will be **published in memo – Magazine of European Medical Oncology**.

Deadline: June 30, 2010

Please submit an abstract online after registering for the conference.
The best posters will receive a poster award!

Registration

Please visit www.bdaoncology.org

Registration fee (Euro)

	full	ESMO members	physicians and scientists in training, students
Early Registration ¹	250,-	150,-	75,-
Late Registration	350,-	250,-	100,-

Members of Tumor Center Munich or Rhein-Main may participate at no charge.

¹payment received before July 30, 2010

Congress Location

Ludwig-Maximilians-Universität München
Lecture Hall, Institute for Chemistry and und Pharmacy
Butenandtstr. 5-13, 81377 Munich

Exhibition

An industrial exhibition will accompany the conference. There will also be other possibilities for the industry to take active part in the conference (e.g. advertisement in the printed final program, sponsoring of the congress bag, etc.). Please contact: btoc@bdaoncology.org for information and registration.

Wednesday, September 8, 2010

- 11.00 a.m. **Start of Registration**
- 12.30 – 12.40 p.m. **Welcome and Introduction**
- 12.40 – 2.45 p.m. **THERAPEUTIC ANTIBODIES FOR PERSONALIZED MEDICINE**
- Monoclonal antibodies – future challenges
H. Chen, Bethesda
- Overcoming primary and secondary resistance mechanisms
t.b.c.
- Predictive value of Fc-receptor polymorphism on ADCC
M. Liljefors, Stockholm
- Monitoring antibody-based therapy of colorectal cancer
A. Bardelli, Torino
- Clinical development of insulin-like growth factor antibodies
S. DiCosimo, Barcelona
- 2.45 – 3.30 p.m. **FREE COMMUNICATIONS**
- 3.30 – 4.15 p.m. **POSTER SESSION / COFFEE BREAK**

- 4.15 – 5.45 p.m. **COMBINATION THERAPY – PRECLINICAL ASPECTS**
- Preclinical biomarker discovery – application of new technologies
G. C. Murray, Nottingham
- Investigation of cancer drug mode of action in presurgical studies
G. Folprecht, Dresden
- The need for combining targeted therapies – taking on new challenges
F. Ciardiello, Naples
- 5.45 – 6.00 p.m. **FREE COMMUNICATIONS**
- 7.30 p.m. **Welcome Reception**

Credit Points for continuous medical education:

The accreditation by ESMO is in progress.

For further details, program updates, registration and abstract submission please visit the conference homepage

www.bdaoncology.org

Thursday, September 9, 2010 - Morning

- 9.00 – 10.40 p.m. **COMBINATION THERAPY – CLINICAL ASPECTS**
- Targeting the PI3K-AKT and Raf-MEK-ERK pathways for the treatment of cancer - novel-novel development
T.Bogenrieder, London
- Preclinical activity of type II CD20 antibody GA101 as single agent and in combination with chemotherapy or targeted agents
C.Klein, Schlieren
- Preclinical and early clinical evaluation of a suitable combination of trifunctional antibodies with chemotherapy
J.Atz, Munich
- Combination of lenalidomide with antibody therapy
J.Loeffler-Ragg, Innsbruck
- 10.40 – 11.00 a.m. **COFFEE BREAK**
- 11.00 – 11.50 a.m. **Combination therapy with everolimus and trastuzumab**
G.Jerusalem, Liège
- Everolimus in combination with octreotide and SOM230
M.Peeters, Edegem
- 11.50 – 12.00 p.m. **FREE COMMUNICATIONS**
- 12.00 – 12.45 p.m. **MicroRNA – KEYNOTE LECTURE**
- Causes and consequences of microRNA dysregulation in cancer
t.b.c.
- Predictive and prognostic biomarker discovery using functional RNA interference approaches
C.Swanton, London
- 12.45 – 1.00 p.m. **FREE COMMUNICATIONS**
- 1.00 – 2.00 p.m. **LUNCH**

Thursday, September 9, 2010 - Afternoon

- 2.00 – 6.00 p.m. **BDA Immunotherapy Working Group together with iSBTc**
- THE INFLUENCE OF MALIGNANT TUMORS ON THE IMMUNE SYSTEM I**
- Welcome and introduction (a short overview, immunosuppression at different levels)
L.Hakansson, Linköping
- KEY NOTE LECTURE: *The immunoediting model***
t.b.c.
- Recruitment of inflammatory cells – role of chemokines
T.Gajewski, Chicago
- Regulation of the migration of inflammatory cells
N.Hogg, London
- Oxidative stress – suppression of intra-tumoral immune reactivity
R.Kiessling, Stockholm
- 4.05 – 4.30 p.m. **COFFEE BREAK**
- 4.30 – 5.20 p.m. **Hypoxia induced immunosuppression – the role of VEGF on the development of dendritic cells and myeloid derived suppressor cells**
D.Gabrilovich, Tampa
- The effect of anti-VEGF therapy on cancer related immunosuppression
T.Osada, Durham
- 5.20 – 6.00 p.m. **FREE COMMUNICATIONS**

Friday, September 10, 2010

9.00 – 10.40 a.m. **BDA Immunotherapy Working Group together with iSBTc**
THE INFLUENCE OF MALIGNANT TUMORS ON THE
IMMUNE SYSTEM II

Fc-receptor mediated immune regulation in cancer
F.Nimmerjahn, Erlangen

Modulation of immune reactivity by intratumoral proteolytic activity
M.Wolf, Bern

Therapeutic effect of antibodies directed against phosphatidyl serine
J.Shan, Tustin

Primary and secondary immunosuppression in cancer
L.Hakansson, Linkoping

10.40 – 11.00 a.m. **COFFEE BREAK**

11.00 – 12.00 a.m. **PANEL DISCUSSION: Immunoregulation in cancer**

12.00 – 1.00 p.m. **LUNCH**

1.00 – 3.15 p.m. **THERAPEUTIC CANCER VACCINES**

Cancer vaccine development strategies
S.Kleif, Bethesda

Risk of vaccination
H.Streicher, Bethesda

Monitoring of cancer vaccine trials
G.Gaudernack, Oslo

DNA vaccination in oncology: Current status, opportunities and perspectives
J.H.van den Berg, Herley

Development of Sipuleucel-T
t.b.c.

3.15 – 4.00 p.m. **FREE COMMUNICATIONS**

4.00 p.m. **End of meeting**

Organizing Committee

L. Bergmann, Germany

B. Fox, USA

L. Hakansson, Sweden

S. Khleif, USA

H. Mellstedt, Sweden

V. Nuessler, Germany

M. Scheulen, Germany

H. Zwierzina, Austria

Contact

BDA congress office | Eugen Preuss, MD
Tel. +43(0)512-579497 | Fax +43(0)512-579497-55

btoc@bdaoncology.org

